Evidence map›Paper›PMID 36221244›Full record

ArticleCancer medicine2023

Remote assessment of cognitive dysfunction in hematologic malignancies using web-based neuropsychological testing.

Oscar Y Franco-Rocha, Misty L Mahaffey, William Matsui, Shelli R Kesler

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Oscar Y Franco-RochaBrain Health Neuroscience Lab, School of Nursing, University of Texas at Austin, Austin, Texas, USA.ORCID 0000-0002-5547-1518
Misty L MahaffeyDepartment of Hematology/Oncology, Stanford Cancer Institute, Stanford Health Care, Palo Alto, California, USA.
William MatsuiDepartment of Oncology, Dell School of Medicine, University of Texas at Austin, Austin, Texas, USA.
Shelli R KeslerBrain Health Neuroscience Lab, School of Nursing, University of Texas at Austin, Austin, Texas, USA.ORCID 0000-0002-4745-8014
The University of Texas at Austin · USStanford Health Care · US

Funding

Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Predicting Long-Term Chemotherapy-Related Cognitive ImpairmentR01CA226080 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI KESLER, SHELLI R, PALESH, OXANA G · 2019 to 2024
$3.1M
NCI NIH HHS R01 CA172145NCI NIH HHS R01 CA226080
6 · The paper itself

Abstract

backgroundCognitive impairment is a frequent adverse effect of cancer and its therapies. As neuropsychological assessment is not often standard of care for patients with non-CNS disease, efficient, practical assessment tools are required to track cognition across the disease course. We examined cognitive functioning using a web-based cognitive testing battery to determine if it could detect differences between patients with cancer and controls.

methodsWe enrolled 22 patients with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL) and 40 healthy controls (mean age = 56 ± 11 years, 52% male). Participants completed the BrainCheck cognitive testing battery and online versions of select measures from the Patient Reported Outcome Measures Information System (PROMIS) during a video conference. MANOVA was used to compare BrainCheck and PROMIS scores between groups controlling for age and sex. An exploratory linear regression analysis was conducted within the cancer group to determine potential contributors to cognitive functioning.

resultsAll participants except for one control completed the online assessment measures without difficulty. Compared to controls, the cancer group demonstrated significantly lower scores in objective and subjective cognitive function, physical functioning, and social role performance and elevated fatigue scores. Corticosteroid treatment, immunotherapy, lower physical functioning, lower income, and older age significantly contributed to lower cognitive function (adjusted R

conclusionRemote assessment of cognitive and psychosocial functioning is feasible with patients with cancer following treatments. The BrainCheck cognitive testing battery has the potential to detect differences in cognition between patients with cancer and controls.

Indexed as

Cognitive DysfunctionHematologic NeoplasmsAgedCognitionFemaleHumansInternetMaleMiddle AgedNeuropsychological Testscognitive functionhematological cancerhematopoietic stem cell transplantationpsychosocial functioningremote assessment

Identifiers

PMID36221244
PMCPMC10028155
OpenAlexW4304758219

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read25
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.